Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.65 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938780 | 1.00 | MEN1 (0.65) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL938781 | 1.00 | MEN1 (0.65) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL2707245 | 0.98 | MEN1 (0.62) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL1764935 | 0.98 | MEN1 (0.62) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL7673446 | 0.98 | MEN1 (0.62) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL20449216 | 0.98 | MEN1 (0.62) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL9080005 | 0.98 | MEN1 (0.62) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| SCHEMBL8544217 | 0.98 | MEN1 (0.62) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL28855198 | 0.96 | CYP2D6 (0.61) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL28855199 | 0.96 | CYP2D6 (0.61) | MEN1CYP2D6CYP2C19KMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049326-A1 | TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-4506035-A2 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-3768668-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-117157285-A | Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors | 阿尔麦克探索有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2022200523-A9 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | BIOARDIS LLC | 2023-02-02 | — | — | US | disclosed |
| EP-4055026-A1 | COMPOUNDS AS CD73 INHIBITORS | Bioardis LLC (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114945578-A | Compounds as CD73 inhibitors | 博奥阿迪斯生物科技公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2009153536-A1 | 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009112845-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | THE UNIVERSITY OF EDINBURGH (GB) | 2009-09-17 | — | — | WO | disclosed |
| US-20080269529-A1 | Chiral Compound Suitable as a Catalyst for Asymmetric Transfer Hydrogenation | PATHEON HOLDINGS I B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| EP-0705259-B1 | PHENYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-02-25 | — | — | EP | disclosed |
| US-5637600-A | PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-06-10 | — | — | US | disclosed |
| EP-0745079-A1 | PHENYLPYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-12-04 | — | — | EP | disclosed |
| EP-0705259-A1 | PHENYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995022542-A1 | PHENYLPYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-08-24 | — | — | WO | disclosed |
| US-5382590-A | Gastrointestinal disorders and nervous system disorders | RHONE-POULENC RORER S.A. (FR) | 1995-01-17 | — | — | US | disclosed |
| WO-1995000508-A1 | PHENYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | ENTPD5, ENTPD1, NT5E | MEN1 2427/4885CYP2D6 2120/4885CYP2C19 2171/4885 |
| US-20220204539-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, ENTPD2 | MEN1 2540/4885CYP2D6 2179/4885CYP2C19 3759/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MEN1 142/4885CYP2D6 33/4885CYP2C19 20/4885 |
| US-20080269529-A1 | Chiral Compound Suitable as a Catalyst for Asymmetric Transfer Hydrogenation | SLC30A6, SLC39A14, SLC30A5 | MEN1 800/4885CYP2D6 2453/4885CYP2C19 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.